Kazuhiro Yoshioka

Continuous daily use of cilostazol prevents in-stent restenosis following carotid artery stenting: serial angiographic investigation of 229 lesions

Background Several studies have reported that cilostazol (CLS) may reduce in-stent restenosis (ISR) after carotid artery stenting (CAS). However, it is not known for how long CLS must be continued to prevent ISR. Methods We retrospectively reviewed a prospectively collected database of patients who underwent elective CAS and follow-up angiography at 3 months and 1 year after the procedure. ISR was defined as stenosis of 50% or greater on digital subtraction angiography. The cumulative incidence rates of angiographic ISR were compared between the three groups, divided according to duration of CLS use : (1) patients who were maintained on CLS for 12 months or more after CAS (12M CLS group, n=70), (2) patients who were treated with CLS for the first 3 months after CAS (3M CLS group, n=23), and (3) patients who did not receive CLS (no CLS group, n=136). Results A total of 229 lesions in 199 patients were included in our analysis. During a median follow-up of 365 days, ISR was detected in 15 lesions. The cumulative ISR rates overall and in the 12M CLS, 3M CLS, and no CLS groups were 5.6%, 0%, 5.0%, and 8.4%, respectively, at 1 year, and the log rank test showed that there was a significant difference between the three groups (p<0.05). Cox regression analysis demonstrated that the 12M CLS group had a significantly lower risk of ISR than the 3M CLS group (adjusted relative risk (aRR) 3.06e-10, 95% CI 0 to 0.51, p<0.05) and the no CLS group (aRR 1.41e-10, 95% CI 0 to 0.15, p<0.001), whereas no difference was found between the 3M CLS group and the no CLS group. Conclusions An overall cumulative ISR rate of 5.6% was documented angiographically at 1 year after CAS. Continuous daily use of CLS (for at least 1 year) may have a beneficial effect on long term prevention of ISR.

Abstract TP368: Effectiveness and Safety of Luseogliflozin, Sodium-Glucose Cotransporter2 Inhibitor, to Treat Hyperglycemia in an Acute Stroke Stage

Introduction: Hyperglycemia found at arrival or after admission must be treated as soon as possible in acute stroke patients, because hyperglycemia impairs their clinical outcome. However, it hasn’...

Measurement of oxygen extraction fraction by blood sampling to estimate severe cerebral hemodynamic failure and anticipate cerebral hyperperfusion syndrome following carotid artery stenting

Background Cerebral hyperperfusion syndrome (CHS) is likely to occur after carotid revascularization in patients with stage 2 hemodynamic failure (st2HF), in whom the oxygen extraction fraction (OEF) increases. Objective The purpose of our study was to investigate whether measurement of the global cerebral OEF (gcOEF) by blood sampling can be used to estimate st2HF and anticipate CHS following carotid artery stenting (CAS). Methods The OEF was calculated by blood sampling just before and after elective CAS. Data were collected prospectively. Patients who underwent elective CAS and gcOEF calculation were included in the study. Patients’ baseline features, pre-CAS gcOEF, post-CAS gcOEF, and incidence of CHS (defined as headache, seizure, focal neurologic deficits, and/or restlessness) were evaluated. Results 141 patients met the inclusion criteria and 134 patients were analyzed. Median pre-CAS gcOEF and post-CAS gcOEF were 0.41 and 0.42, respectively. Nine patients developed CHS. Median pre-CAS gcOEF was higher in patients with than in those without CHS (Mann–Whitney U test, P<0.05), but median post-CAS gcOEF was not significantly higher in patients with CHS (P=0.058). Scattergrams of patients with and without CHS showed that the cut-off values of the pre-CAS gcOEF and post-CAS gcOEF for anticipation of CHS were 0.46 (P<0.01) and 0.49 (P<0.001), respectively. Conclusion Elevation of the pre-CAS or post-CAS gcOEF by blood sampling allowed for anticipation of CHS following CAS. Elevation of the pre-CAS gcOEF might be associated with st2HF.

Subacute Percutaneous Cerebral Balloon Angioplasty for Middle Cerebral Artery Occlusion in Patients with Internal Border Zone Infarcts

Background We report our initial experiences of subacute percutaneous cerebral balloon angioplasty (PTCBA) for atherothrombotic middle cerebral artery (MCA) occlusion in patients with internal border zone (IBZ) infarcts more than 1 week after stroke onset. Methods Included in the retrospective analysis were patients (1) who were admitted to our institution between 3 and 72 hours after an atherothrombotic stroke onset, (2) whose diffusion‐weighted image at admission showed small high‐intensity lesions in the IBZ area, (3) whose magnetic resonance angiography at admission displayed the MCA occlusion, (4) whose computed tomography scans on day 7 showed the IBZ infarcts, (5) whose National Institutes of Health Stroke Scale (NIHSS) score was ≥ 10 on day 7, and (6) whose neurologic symptoms deteriorated day by day within 7 days of onset (a > 4‐point increase on the NIHSS) despite medical therapy. Results Ten patients met our criteria and were informed of their treatment options including angioplasty and/or stenting for atherothrombotic MCA occlusion in a subacute stroke stage. Four patients gave written informed consent and underwent subacute PTCBA; six did not. Although there were no significant differences in the prestroke modified Rankin Scale (mRS), NIHSS on admission and NIHSS on day 7 after onset between the two groups, 3‐month mRS score (median) was 3 in the PTCBA group and 5 in the medical treatment group (p < 0.05). Conclusion Subacute PTCBA for atherothrombotic MCA occlusion may be effective in improving long‐term clinical outcome in patients with IBZ infarcts.